Fulcrum Therapeutics, Inc. FULC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -67.20%
- 1 year
- -56.86%
- Open
- 3.74
- Prev close
- 3.77
- Mkt cap
- 283.38M
- Vol
- 933.22K
- Avg vol
- 1.53M
- EPS
- -1.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.68
- High
- 3.76
- Forward P/E
- -3.84
- Beta
- 2.23
- Short ratio
- 7.67
- Inst. own
- 89.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 3.58
- 200-d avg
- 6.57
- 1y target
- 5.29
News
1 week ago defenseworld.net
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Average Target Price of $8.20
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have been assigned an average recommendation of "Reduce" from the twelve research firms that are presently covering the stock,…
2 weeks ago gurufocus.com
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
2 weeks ago prnewswire.com
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
3 weeks ago newsfilecorp.com
Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the…
3 weeks ago newsfilecorp.com
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the…
1 month ago newsfilecorp.com
Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the…
1 month ago newsfilecorp.com
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago newsfilecorp.com
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation
New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago defenseworld.net
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Reduce” from Brokerages
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the twelve research firms that are presently covering the company,…
1 month ago newsfilecorp.com
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
1 month ago newsfilecorp.com
Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago newsfilecorp.com
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Learn More About the Firm's Investigation
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago defenseworld.net
Reviewing Fulcrum Therapeutics (NASDAQ:FULC) & Biogen (NASDAQ:BIIB)
Biogen (NASDAQ: BIIB - Get Free Report) and Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
1 month ago newsfilecorp.com
Kaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago gurufocus.com
Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?
Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 15, 2026Insiders may stand to receive substantial financial benefits
1 month ago newsfilecorp.com
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Investors Who Suffered Losses
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago newsfilecorp.com
Kaplan Fox Urges Investors of Fulcrum Therapeutics, Inc. (FULC) with Losses to Contact the Firm
New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
1 month ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
1 month ago newsfilecorp.com
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (FULC) of an Ongoing Securities Investigation
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or…
2 months ago benzinga.com
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
-
2 months ago benzinga.com
Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage,…
-
5 months ago benzinga.com
UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges
On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following…
5 months ago benzinga.com
What's Going On With Fulcrum Therapeutics Stock On Thursday?
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.
5 months ago benzinga.com
This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade TMHC and SARO respectively. See more views.
-
5 months ago benzinga.com
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
-
5 months ago benzinga.com
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3
Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight and lowers the price target from $23 to $3.
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
5 months ago benzinga.com
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.
-
5 months ago benzinga.com
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and lowers the price target from $24 to $4.
5 months ago benzinga.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, HPQ target raised, PRAX target cut, GNSS target raised, INTU target lowered, GH target raised, CRDO…
5 months ago benzinga.com
This Goldman Sachs Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday
Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC, INTU, NU.
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
5 months ago benzinga.com
HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $3
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the price target from $25 to $3.
5 months ago benzinga.com
Why Hewlett Packard Enterprise Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. Top losers are FULC, JZ, and more.
-
5 months ago benzinga.com
FULC Stock Crashes After Hours: What Investors Need To Know
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
5 months ago benzinga.com
Fulcrum Therapeutics Launches Strategic Alternatives Review To Maximize Shareholder Value
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage…
-
5 months ago benzinga.com
Fulcrum Discontinues Pociredir Program For Treatment Of Sickle Cell Disease After FDA Flags Concerns About Malignancy Risk From PRC2 Inhibitors
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA. The minutes reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD,…
-
6 months ago benzinga.com
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript
6 months ago benzinga.com
Earnings Scheduled For April 27, 2026
Earnings Scheduled For April 27, 2026
6 months ago benzinga.com
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market trading after beating analyst estimates.
7 months ago benzinga.com
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
7 months ago benzinga.com
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
-
7 months ago benzinga.com
MedicAlert Foundation, SCDAA And Fulcrum Therapeutics Partner To Help Streamline And Expedite ED Care For People Living With Sickle Cell Disease Through Rapid Access To Patient-Specific Care Plans
MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
8 months ago benzinga.com
What's Going On With Fulcrum Therapeutics Stock Tuesday?
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease patients.
-
8 months ago benzinga.com
Fulcrum Therapeutics Q4 EPS $(0.31), Inline
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
-
8 months ago benzinga.com
Fulcrum Therapeutics Reports 12-Week Results From 20 Mg Dose Cohort Of Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session